SCHEDULE 13G/A: Adage Capital Management Discloses 5.62% Passive Stake in Mereo BioPharma Group plc
Beneficial Ownership Report
Adage Capital Management, L.P. and its principals have disclosed a passive beneficial ownership of 5.62% in Mereo BioPharma Group plc, holding 43,575,065 ordinary shares as of December 31, 2024.
Summary
- Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported beneficial ownership of 43,575,065 ordinary shares of Mereo BioPharma Group plc.
- This stake represents 5.62% of the company's outstanding ordinary shares.
- The ownership percentage is calculated based on 775,728,034 ordinary shares outstanding as of November 11, 2024, as reported in the company's Form 10-Q.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a passive investment purpose, meaning the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- Adage Capital Partners GP, L.L.C. is no longer a beneficial owner of securities held by ACP but is submitting the filing under its CIK number to gain access to the EDGAR system for structured data requirements.
Sentiment
Score: 7
Explanation: The disclosure of a significant passive stake by a reputable investment manager like Adage Capital Management is generally viewed positively by the market, indicating potential investor confidence in Mereo BioPharma Group plc.
Positives
- Adage Capital Management, a notable investment firm, has disclosed a significant passive stake of 5.62% in Mereo BioPharma Group plc, potentially signaling confidence in the company's long-term prospects.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: The disclosure of a significant passive stake by a major investment firm may instill confidence and potentially influence market perception of the company's value.
Key Dates
| Date | Description |
|---|---|
| 2024-11-11 | Date as of which 775,728,034 Ordinary Shares outstanding were reported in the Company's Form 10-Q. |
| 2024-11-12 | Date the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2024, was filed with the SEC. |
| 2024-12-18 | Effective date for structured data requirements applicable to Schedule 13G filings. |
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership determination date). |
| 2025-02-12 | Filing date of the Schedule 13G/A. |
Keywords
Mereo BioPharma Group plc, Adage Capital Management, Schedule 13G, Beneficial Ownership, MREO, Biopharma, Investment, Passive Stake, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.